NovaBridge Biosciences (NBP) EBITDA Margin (2020 - 2023)
NovaBridge Biosciences (NBP) reported EBITDA Margin of 3375.87% for Q3 2023, up 55.46% on a QoQ basis from 7578.62% in Q2 2023.
NovaBridge Biosciences (NBP) has 2 years of EBITDA Margin data on file, last reported at 3375.87% in Q3 2023.
- Quarterly EBITDA Margin changed N/A year-over-year to 3375.87% in Q3 2023, while the trailing twelve-month figure through Sep 2023 was 4391386.42% (changed N/A YoY) and the FY2023 annual result came in at 5264.46%, down 2882771.0% from the prior year.
- EBITDA Margin grew to 3375.87% in Q3 2023 per NBP's latest filing, from 7578.62% in the prior quarter.
- Across five years, EBITDA Margin topped out at 3375.87% in Q3 2023 and bottomed at 31714.02% in Q4 2020.
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -3,375.87% |
| Jun 30, 2023 | -7,578.62% |
| Dec 31, 2020 | -31,714.02% |